Torley Helen, PRES, reported an open-market or private sale at HALOZYME THERAPEUTICS, INC. involving 9900.000000 shares for an estimated $761666.40. Reported holdings after the transaction were 718819.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
PRESIDENT AND CEO
The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of comm…
Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.450 to $75.442. The Reporting Person has provided to the issuer, and will provide to any security h…
Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.470 to $76.460. The Reporting Person has provided to the issuer, and will provide to any security h…
Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.490 to $77.030. The Reporting Person has provided to the issuer, and will provide to any security h…
Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.275 to $77.260. The Reporting Person has provided to the issuer, and will provide to any security h…
Represents a weighted average sales price per share. The shares were sold at prices ranging from $77.290 to $77.990. The Reporting Person has provided to the issuer, and will provide to any security h…
Represents a weighted average sales price per share. The shares were sold at prices ranging from $77.640 to $78.637. The Reporting Person has provided to the issuer, and will provide to any security h…
Represents a weighted average sales price per share. The shares were sold at prices ranging from $78.643 to $79.292. The Reporting Person has provided to the issuer, and will provide to any security h…
Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant wa…
0 other filings
0 recent txs